News and Announcements
Crowd Mobile Annual Update 2016; $3M Equity Capital Raise & 192% Increase in Net Revenue
- Published January 31, 2017 5:04PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
The 2016 financial year was Crowd Mobile’s first full year as an ASX Listed business, for Crowd Mobile it was a year of accomplishment and expansion.
- 192% increase in net revenue prior to the year before $37.9 million.
- Major growth in revenue from the newly generated mobile subscription which contributed to $17.2 million for the last eight months of the financial year.
- The original Q & A division grew to $20.7 million during 2016 (up 61.7% from $12.8 million in 2015 FY)
- $3 million equity capital raise.
Company Updates
The Biofilm Breakthrough: How An Australian BioTech Firm Is Tapping Indonesia’s $45,000-a-Kitchen Bottleneck
Australian sustainability and deep-tech firm Altair International Pty Ltd is commercialising plant-based clinical hygiene technology, targeting a prime operational bottleneck in Indonesia’s massive national free meals program. Every few years, an Australian deep-tech company emerges combining proprietary science with a transformational anchor contract, the kind of business that quietly creates an entirely new market category […]
THE TAX CHANGED. NOW THE PRODUCT IS CHANGING TO MATCH.
Changes to the 50% capital gains tax discount are shifting Australian private capital away from growth and into high-yielding wrappers. Fund managers are actively redesigning products across private credit and property to capture the incoming capital rotation
The Algorithm Re-Dosing Cancer Treatment: Inside the University of Melbourne Spin-Out Rewriting a 60-Year-Old Formula
Oncology specialists are still calculating toxic chemotherapy doses using a formula from the era of the Ford Model T, leading to a system where seven out of eight patients are routinely overdosed. University of Melbourne spin-out PredicTx is dismantling this legacy approach, utilizing advanced AI to analyze existing patient CT scans, deliver precision medicine to the bedside, and return a massive 100x financial rerate to hospital networks.
Backed By Leading Investment Groups and Family Offices
